Richard Bartram serves as Chief Financial Officer at MBX Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing innovative peptide therapeutics for endocrine and metabolic disorders. With more than 25 years of experience in biotechnology finance, Bartram previously held senior leadership roles at Genentech and Gilead Sciences, where he spearheaded financial operations, capital raises, and strategic mergers. He earned his MBA from the Wharton School of the University of Pennsylvania and a BS in Accounting from the University of Michigan. Bartram's career is marked by significant achievements, including orchestrating over $2 billion in equity and debt financings for biotech firms and guiding three companies through successful NASDAQ IPOs. At Gilead, he optimized cost structures during a period of rapid expansion, reducing operational expenses by 30% while accelerating pipeline advancements. His expertise in regulatory financial reporting and investor relations has earned him recognition as a thought leader, with features in BioPharm International and Forbes. In his current role at MBX Biosciences, Bartram drives the company's financial strategy to support late-stage clinical trials for its lead candidates in hypoparathyroidism and obesity. He collaborates closely with the executive team to secure partnerships and funding, ensuring MBX's position at the forefront of peptide innovation and sustainable growth in the competitive biopharma landscape.